CytoDyn Collaborates with UK’s Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19

 CytoDyn Collaborates with UK’s Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19

CytoDyn Collaborates with UK’s Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19

Shots:

  • CytoDyn is collaborating with the UK’s Department of Health to provide emergency access to its investigational therapy, leronlimab to treat patients with COVID-19. The MHRA’s submission is expected to be made soon to include clinical sites in the UK
  • The US FDA has approved the initiation of its P-IIb/III clinical study for severe and critically ill COVID-19 patients for which enrollment is in progress.  The P-IIb/III study will assess leronlimab (q2w) vs PBO in 390 patients in a ratio 2:1 with its 1EPs as mortality rate @28days and 2EPs as mortality rate @14days
  • CytoDyn has initiated enrollment in a P-II clinical study for mild-to-moderate COVID-19 patients in the US. Leronlimab is an IgG4 mAb that blocks CCR5 and has received the US FDA’s FT designation as a combination therapy with HAART for HIV infected patients and for metastatic triple-negative BC

Click here ­to­ read full press release/ article | Ref: CytoDyn | Image: CytoDyn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post